Suppr超能文献

慢性肾脏病(CKD)和终末期肾病(ESRD)患者静脉内膜病变中血浆糜酶浓度升高及肥大细胞糜酶表达增加。

Increased plasma chymase concentration and mast cell chymase expression in venous neointimal lesions of patients with CKD and ESRD.

作者信息

Wasse Haimanot, Rivera Angel A, Huang Rong, Martinson Deborah E, Long Qi, McKinnon William, Naqvi Nawazish, Husain Ahsan

机构信息

Division of Nephrology, Emory University, Atlanta, Georgia 30322, USA.

出版信息

Semin Dial. 2011 Nov-Dec;24(6):688-93. doi: 10.1111/j.1525-139X.2011.00921.x. Epub 2011 Jul 22.

Abstract

The underlying inflammatory component of chronic kidney disease may predispose blood vessels to intimal hyperplasia (IH), which is the primary cause of dialysis access failure. We hypothesize that vascular pathology and markers of IH formation are antecedent to arteriovenous (AV) fistula creation. Blood, cephalic, and basilic vein segments were collected from predialysis chronic kidney disease (CKD) patients with no previous AV access and patients with end-stage renal disease (ESRD). Immunohistochemistry was performed with antibodies against mast cell chymase, transforming growth factor-beta (TGF-β) and interleukin-6 (IL-6), which cause IH. Plasma chymase was measured by ELISA. IH was present in 91% of CKD and 75% of ESRD vein segments. Chymase was abundant in vessels with IH, with the greatest expression in intima and medial layers, and virtually absent in the controls. Chymase colocalized with TGF-β1 and IL-6. Plasma chymase concentration was elevated up to 33-fold in patients with CKD versus controls and was associated with increased chymase in vessels with IH. We show that chymase expression in vessels with IH corresponds with plasma chymase concentrations. As chymase inhibition attenuates IH in animal models, and we find chymase is highly expressed in IH lesions of patients with CKD and ESRD, we speculate that chymase inhibition could have therapeutic value in humans.

摘要

慢性肾脏病潜在的炎症成分可能使血管易发生内膜增生(IH),而内膜增生是透析通路失败的主要原因。我们推测血管病变和内膜增生形成的标志物先于动静脉(AV)内瘘的建立。从既往无AV通路的透析前慢性肾脏病(CKD)患者和终末期肾病(ESRD)患者中采集血液、头静脉和贵要静脉段。用抗肥大细胞糜酶、转化生长因子-β(TGF-β)和白细胞介素-6(IL-6)的抗体进行免疫组织化学检测,这些物质可导致内膜增生。通过酶联免疫吸附测定法检测血浆糜酶。91%的CKD静脉段和75%的ESRD静脉段存在内膜增生。糜酶在有内膜增生的血管中大量存在,在内膜和中层表达最高,而在对照组中几乎不存在。糜酶与TGF-β1和IL-6共定位。与对照组相比,CKD患者的血浆糜酶浓度升高高达33倍,且与有内膜增生的血管中糜酶增加有关。我们发现有内膜增生的血管中糜酶表达与血浆糜酶浓度相对应。由于在动物模型中糜酶抑制可减轻内膜增生,且我们发现糜酶在CKD和ESRD患者的内膜增生病变中高度表达,因此我们推测糜酶抑制对人类可能具有治疗价值。

相似文献

2
Effect of chymase inhibition on the arteriovenous fistula stenosis in dogs.糜酶抑制对犬动静脉内瘘狭窄的影响。
J Am Soc Nephrol. 2005 Apr;16(4):1024-34. doi: 10.1681/ASN.2003121009. Epub 2005 Mar 2.
4
Severe venous neointimal hyperplasia prior to dialysis access surgery.透析通路术前严重静脉内膜增生。
Nephrol Dial Transplant. 2011 Jul;26(7):2264-70. doi: 10.1093/ndt/gfq733. Epub 2011 Jan 10.
10

引用本文的文献

4
Mast cells in human and experimental cardiometabolic diseases.人类和实验性心血管代谢疾病中的肥大细胞。
Nat Rev Cardiol. 2015 Nov;12(11):643-58. doi: 10.1038/nrcardio.2015.117. Epub 2015 Aug 11.
7
Novel paradigms for dialysis vascular access: Introduction.透析血管通路的新范例:引言
Clin J Am Soc Nephrol. 2013 Dec;8(12):2183-5. doi: 10.2215/CJN.03650413.
8
Objectives and design of the hemodialysis fistula maturation study.血液透析瘘成熟研究的目的和设计。
Am J Kidney Dis. 2014 Jan;63(1):104-12. doi: 10.1053/j.ajkd.2013.06.024. Epub 2013 Aug 28.

本文引用的文献

2
Coronary stents: current status.冠状动脉支架:现状。
J Am Coll Cardiol. 2010 Aug 31;56(10 Suppl):S1-42. doi: 10.1016/j.jacc.2010.06.007.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验